Article: Drugs U-turn brings kidney cancer boost

KIDNEY cancer patients across Scotland are set to get a costly life-prolonging drug on the NHS after a U-turn in guidance for doctors.

Campaigners were celebrating last night after drugs watchdogs issued advice stating that the drug Sutent (sunitinib) should be made available to patients who might benefit.

It was initially rejected for use in Scotland in 2007, leaving many patients having to fund the treatment themselves at a cost of thousands of pounds.

But yesterday, NHS Quality Improvement Scotland (NHS QIS) announced the drug would now be available through the health service following an announcement by experts in England.

It is thought more than 100 patients a year in Scotland could ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!